Ikena Oncology (IKNA) Moves to Buy: Rationale Behind the Upgrade [Yahoo! Finance]
Ikena Oncology, Inc. (NASDAQ: IKNA) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $2.00 price target on the stock.
Ikena Oncology and Inmagene Biopharmaceuticals Announce Agreement for Merger and Private Placement [Yahoo! Finance]
Ikena Oncology and Inmagene Biopharmaceuticals Announce Agreement for Merger and Private Placement
Ikena Oncology, Inc. (NASDAQ: IKNA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $4.00 price target on the stock.